/APLS

APLS Stock - Apellis Pharmaceuticals, Inc.

Q: What is the analyst price target for APLS?

Analyst price target information is not currently available for APLS.

Q: What is APLS's market cap?

Market capitalization information is not currently available for APLS.

Healthcare|Biotechnology|NASDAQ

$21.33-8.06%

$1.87 (-8.06%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+60.6%upside

Target: $34.26

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for APLS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.30

52W High$31.17

52W Low$16.10

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$781.37M	$396.59M	$75.42M	$66.56M	$250.65M
Gross Profit	$663.64M	$338.08M	$69.79M	$61.36M	$225.60M
Gross Margin	84.9%	85.2%	92.5%	92.2%	90.0%
Operating Income	$-164,979,000	$-517,121,000	$-594,613,000	$-536,277,000	$-213,726,000
Net Income	$-197,878,000	$-528,628,000	$-652,172,000	$-746,354,000	$-344,874,000
Net Margin	-25.3%	-133.3%	-864.7%	-1121.3%	-137.6%
EPS	$-1.60	$-4.45	$-6.15	$-8.84	$-4.59

Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Visit Website

Earnings History & Surprises

APLS

Beat Rate

33%

Last 18 quarters

Avg Surprise

-10.6%

EPS vs Estimate

Beats / Misses

6/11

1 met exactly

Latest EPS

$1.67

Q4 2025

EPS Surprise History

Q1 24

-10.6%

$-0.73vs$-0.66

Q2 24

0.0%

$-0.54vs$-0.54

Q3 24

+15.2%

$-0.28vs$-0.33

Q4 24

-43.8%

$-0.46vs$-0.32

Q1 25

+21.6%

$-0.29vs$-0.37

Q2 25

-105.6%

$-0.74vs$-0.36

Q3 25

+25.0%

$-0.33vs$-0.44

Q4 25

+62.1%

$1.67vs$1.03

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 5, 2026	—	—	—	—
Q1 2026	Feb 27, 2026	$-0.41	—	—	—
Q4 2025	Oct 30, 2025	$1.03	$1.67	+62.1%	✓ BEAT
Q3 2025	Jul 31, 2025	$-0.44	$-0.33	+25.0%	✓ BEAT
Q2 2025	May 7, 2025	$-0.36	$-0.74	-105.6%	✗ MISS
Q1 2025	Feb 28, 2025	$-0.37	$-0.29	+21.6%	✓ BEAT
Q4 2024	Nov 5, 2024	$-0.32	$-0.46	-43.8%	✗ MISS
Q3 2024	Aug 1, 2024	$-0.33	$-0.28	+15.2%	✓ BEAT
Q2 2024	May 7, 2024	$-0.54	$-0.54	0.0%	= MET
Q1 2024	Feb 27, 2024	$-0.66	$-0.73	-10.6%	✗ MISS
Q4 2023	Nov 1, 2023	$-0.84	$-1.17	-39.3%	✗ MISS
Q3 2023	Jul 31, 2023	$-1.35	$-1.02	+24.4%	✓ BEAT
Q2 2023	May 4, 2023	$-1.42	$-1.56	-9.9%	✗ MISS
Q1 2023	Feb 21, 2023	$-1.65	$-1.50	+9.1%	✓ BEAT
Q4 2022	Nov 7, 2022	$-1.48	$-1.75	-18.2%	✗ MISS
Q3 2022	Aug 8, 2022	$-1.43	$-1.46	-2.1%	✗ MISS
Q2 2022	May 4, 2022	$-1.36	$-1.42	-4.4%	✗ MISS
Q1 2022	Feb 28, 2022	$-1.32	$-1.61	-22.0%	✗ MISS
Q4 2021	Nov 8, 2021	$-1.73	$-2.28	-31.8%	✗ MISS
Q3 2021	Aug 9, 2021	$-1.70	$-2.72	-60.0%	✗ MISS

Frequently Asked Questions about APLS

What is APLS's current stock price?

Apellis Pharmaceuticals, Inc. (APLS) is currently trading at $21.33 per share. The stock has moved -8.06% today.

What is the analyst price target for APLS?

The average analyst price target for APLS is $34.25, based on 1 analyst.

What sector is Apellis Pharmaceuticals, Inc. in?

Apellis Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is APLS's market cap?

Apellis Pharmaceuticals, Inc. has a market capitalization of $2.70 billion, making it a mid-cap company.

Does APLS pay dividends?

No, Apellis Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.